Previse, recently rebranded from Capsulomics, is a precision-oncology company focused on the early detection and prevention of cancer, beginning with esophageal malignancies. Its first laboratory-developed test, Esopredict™, analyzes DNA methylation changes in four genes from Barrett’s esophagus tissue to generate an Esoscore™ that forecasts a patient’s five-year risk of developing high-grade dysplasia or esophageal cancer. The test equips gastroenterologists with data to personalize surveillance and treatment, aiming to improve outcomes in a cancer that currently has only a 20 % five-year survival rate. Previse’s technology stems from decades of research in the GI Early Detection Biomarker Lab at the Johns Hopkins University School of Medicine and was advanced with National Institutes of Health grants. Following the launch of Esopredict™, the company intends to expand commercial operations and undertake prospective clinical-utility studies to secure broad insurance coverage and reimbursement. Financially, Previse has just raised a $3 million seed round to support these initiatives.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2023